干眼症眼药水立他司特滴眼液的治疗效果

Introduction: In July 2016, the U.S. Food and Drug Administration (FDA) approved the application for ophthalmic solution, which marked a new treatment option for dry eye patients. Lifitegrast can effectively relieve dry eye symptoms by antagonizing the combination of ICAM-1 and LFA-1. It has significant efficacy, low incidence of adverse reactions, and relatively mild symptoms. The launch of this drug will undoubtedly bring good news to dry eye patients, allowing them to have a more comfortable and healthy visual experience.

Pharmacological effects

The mechanism of action of Ritalast is mainly reflected in its characteristics as a small molecule integrin protein antagonist. Its structure is similar to the antigenic determinant of ICAM-1 and can competitively antagonize the binding process of ICAM-1 and LFA-1. Through this antagonism, Ritalast successfully blocks the inflammatory response mediated by T cells, thereby achieving the purpose of treating inflammatory diseases such as dry eye syndrome. This unique mechanism of action makes Ritalast excellent in controlling inflammation levels and provides a new and effective means for the treatment of inflammatory diseases.

Therapeutic effect of Ribalast eye drops

In the phase III trial OPUS-2, 718 patients with moderate to severe dry eye disease received 5% Lifitegrast and placebo, twice daily for 84 days, lifitegrast significantly improved VAS-EDS from 14 days to 84 days after baseline (meeting the primary endpoint) and was superior to placebo in reducing ODS (84 days after baseline). In the phase III trial OPUS-3, 711 patients with moderate to severe dry eye received 5% Lifitegrast or placebo twice daily for 84 days. Lifitegrast also significantly improved VAS-EDS (reaching the primary endpoint) from 14 days to 84 days after baseline, and significantly improved other symptoms: itching, foreign body sensation and eye discomfort at 42 days of treatment.

Safety

The trial found that the most common adverse reactions when using Litalast were dysgeusia (change in taste) and common reactions caused by eye drops (such as irritation). Most of these adverse reactions are temporary and mild to moderate. No serious ocular adverse reactions related to the drug were reported, and no local or systemic immunosuppressive events occurred.